TMC435-TiDP16-C208 - Phase III Trial of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients (QUEST-1)

This study has been completed.
Information provided by (Responsible Party):
Janssen R&D Ireland Identifier:
First received: January 7, 2011
Last updated: July 9, 2013
Last verified: July 2013

The purpose of this study is to investigate the effectiveness and safety of TMC435 compared with placebo in patients who are infected with genotype 1 hepatitis C virus who have never received treatment before. Patients will also receive peginterferon alfa-2a and ribavirin as part of their treatment.

Condition Intervention Phase
Hepatitis C
Drug: Placebo
Drug: TMC435
Phase 3

Janssen R&D Ireland has indicated that access to an investigational treatment associated with this study is available outside the clinical trial.  

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: A Phase III, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of TMC435 vs. Placebo as Part of a Treatment Regimen Including Peginterferon Alfa-2a and Ribavirin in Treatment-naive, Genotype 1 Hepatitis C-infected Subjects

Resource links provided by NLM:

Further study details as provided by Janssen R&D Ireland:

Primary Outcome Measures:
  • The proportion of patients with a sustained virologic response (SVR) 24 weeks after the planned end of treatment [ Time Frame: 24 weeks after planned end of treatment ] [ Designated as safety issue: Yes ]

Enrollment: 395
Study Start Date: February 2011
Study Completion Date: January 2013
Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 001
TMC435 150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a and ribavirin for 24 or 48 weeks
Drug: TMC435
150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a and ribavirin for 24 or 48 weeks
Placebo Comparator: 002
Placebo 150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a and ribavirin for 48 weeks
Drug: Placebo
150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a and ribavirin for 48 weeks

Detailed Description:

This is a randomized, double-blind (neither physician nor patients know the name of the assigned drug), placebo-controlled study of TMC435 in patients who are infected with genotype 1 hepatitis C virus, who have never received treatment for this before. Patients in this study will also receive two other drugs for their infection called peginterferon alfa-2a and ribavirin. The purpose of the study is to investigate if TMC435 is superior to placebo in reducing hepatitis C virus to an undetectable level 24 weeks after the end of treatment. For the first 12 weeks, patients will take either TMC435 or placebo, plus peginterferon alfa-2a and ribavirin. For the next 12 weeks, patients will take peginterferon alfa-2a and ribavirin only. After that, some patients will continue to take peginterferon alfa-2a and ribavirin for up to 24 additional weeks. Other patients will stop taking peginterferon alfa-2a and ribavirin. The study doctor will inform each patient about how to take their study medication and when they should stop taking it. After a patient stops taking study medication, they will continue to come to the doctor's office for study visits until a total of 72 weeks after they enroll in the study. The total duration of the study is 78 weeks (including screening). Patients will be monitored for safety throughout the study. Study assessments at each study visit may include, but are not limited to: blood and urine collection for testing, ECG assessments (a measurement of the electrical activity of your heart), patient questionnaires, and physical examinations. TMC435 will be taken as an oral capsule of 150 mg once per day. Peginterferon (Pegasys ®) will be given as an injection of 180 µg once each week. Ribavirin (Copegus ®) will be taken as a tablet twice each day and the dose will depend on your body weight.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Genotype 1 hepatitis C infection (confirmed at screening)
  • patient has not received any prior treatment for hepatitis C
  • patient must have had a liver biopsy within 3 years before screening (or between the screening and baseline visit) showing chronic hepatitis C infection
  • must agree to use 2 forms of effective contraception throughout study (both males and females).

Exclusion Criteria:

  • Infection with HIV or non genotype 1 hepatitis C
  • liver disease not related to hepatitic C infection
  • hepatic decompensation
  • significant laboratory abnormalities or other active diseases
  • pregnant or planning to become pregnant
  Contacts and Locations
Please refer to this study by its identifier: NCT01289782

  Hide Study Locations
United States, Alabama
Dothan, Alabama, United States
Hoover, Alabama, United States
United States, Arizona
Phoenix, Arizona, United States
United States, California
Bakersfield, California, United States
Coronado, California, United States
Long Beach, California, United States
San Diego, California, United States
United States, Colorado
Aurora, Colorado, United States
Englewood, Colorado, United States
United States, Florida
Miami, Florida, United States
United States, Illinois
Chicago, Illinois, United States
United States, Mississippi
Jackson, Mississippi, United States
Tupelo, Mississippi, United States
United States, Missouri
Saint Louis, Missouri, United States
United States, New York
New York, New York, United States
United States, North Carolina
Chapel Hill, North Carolina, United States
United States, Ohio
Cincinnati, Ohio, United States
United States, Pennsylvania
Philadelphia, Pennsylvania, United States
United States, Tennessee
Nashville, Tennessee, United States
United States, Texas
Dallas, Texas, United States
Houston, Texas, United States
San Antonio, Texas, United States
Darlinghurst, Australia
Fitzroy, Australia
Kingswood, Australia
Melbourne, Australia
Sydney, Australia
Wolloongabba, Australia
Canada, Alberta
Calgary, Alberta, Canada
Canada, Ontario
Ottawa, Ontario, Canada
Toronto, Ontario, Canada
Canada, Quebec
Montreal, Quebec, Canada
Berlin, Germany
Heidelberg, Germany
Kiel, Germany
Tübingen, Germany
Zefat, Israel
Guadalajara, Jalisco, Mexico
Mex Ctity, Mexico
Monterrey, Mexico
New Zealand
Auckland, New Zealand
Christchurch, New Zealand
Hamilton, New Zealand
Puerto Rico
San Juan, Puerto Rico
Bucuresti, Romania
Russian Federation
Moscow, Russian Federation
Nizhny Novgorod, Russian Federation
Saint-Petersburg, Russian Federation
Samara, Russian Federation
Smolensk, Russian Federation
St Petersburg, Russian Federation
Barcelona, Spain
Madrid, Spain
Sevilla N/A, Spain
Valencia, Spain
Donetsk, Ukraine
Kiev, Ukraine
Kyiv, Ukraine
Vinnytsia, Ukraine
United Kingdom
Derby, United Kingdom
Liverpool, United Kingdom
London, United Kingdom
Nottingham, United Kingdom
Plymouth, United Kingdom
Sponsors and Collaborators
Janssen R&D Ireland
Study Director: Janssen R&D Ireland Clinical Trial Janssen R&D Ireland
  More Information

No publications provided

Responsible Party: Janssen R&D Ireland Identifier: NCT01289782     History of Changes
Other Study ID Numbers: CR017386, TMC435-TiDP16-C208
Study First Received: January 7, 2011
Last Updated: July 9, 2013
Health Authority: United States: Food and Drug Administration
Ireland: Irish Agriculture and Food Development Authority
Australia: Department of Health and Ageing Therapeutic Goods Administration
Canada: Health Canada
Germany: Ethics Commission
Great Britain: Medicines and Healthcare Products Regulatory Agency
Ukraine: State Pharmacological Center - Ministry of Health

Keywords provided by Janssen R&D Ireland:
Hepatitis C
Hep C
genotype 1

Additional relevant MeSH terms:
Hepatitis A
Hepatitis C
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections
Peginterferon alfa-2a
Antiviral Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Molecular Mechanisms of Pharmacological Action
Immunologic Factors
Physiological Effects of Drugs processed this record on April 17, 2014